Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanoma | 36 | 2022 | 5508 | 2.990 |
Why?
|
Sentinel Lymph Node Biopsy | 12 | 2021 | 710 | 2.340 |
Why?
|
Skin Neoplasms | 31 | 2021 | 5691 | 2.200 |
Why?
|
Lymph Node Excision | 12 | 2021 | 1262 | 1.210 |
Why?
|
Lymph Nodes | 8 | 2019 | 3476 | 1.160 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 7 | 2020 | 85 | 1.010 |
Why?
|
Lymphatic Metastasis | 15 | 2019 | 2924 | 0.720 |
Why?
|
Inguinal Canal | 1 | 2019 | 69 | 0.700 |
Why?
|
Ilium | 1 | 2019 | 155 | 0.660 |
Why?
|
Leiomyosarcoma | 2 | 2020 | 477 | 0.650 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2020 | 1770 | 0.580 |
Why?
|
Australia | 12 | 2021 | 1167 | 0.540 |
Why?
|
Neoplasm Recurrence, Local | 12 | 2020 | 9239 | 0.520 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1063 | 0.490 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2017 | 340 | 0.470 |
Why?
|
Breast Neoplasms | 22 | 2020 | 20827 | 0.450 |
Why?
|
Neoplasm Staging | 19 | 2021 | 11036 | 0.410 |
Why?
|
Acetone | 1 | 2011 | 43 | 0.400 |
Why?
|
Head and Neck Neoplasms | 4 | 2020 | 2736 | 0.400 |
Why?
|
Methanol | 1 | 2011 | 85 | 0.390 |
Why?
|
Melanocytes | 1 | 2014 | 515 | 0.380 |
Why?
|
Groin | 1 | 2011 | 105 | 0.380 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 1596 | 0.380 |
Why?
|
Quality of Life | 4 | 2019 | 12788 | 0.360 |
Why?
|
Mammography | 5 | 2018 | 2475 | 0.360 |
Why?
|
Skin | 3 | 2020 | 4372 | 0.320 |
Why?
|
Titanium | 1 | 2011 | 487 | 0.320 |
Why?
|
Melphalan | 6 | 2020 | 431 | 0.320 |
Why?
|
Preoperative Care | 1 | 2017 | 2251 | 0.320 |
Why?
|
Soft Tissue Neoplasms | 1 | 2017 | 1363 | 0.300 |
Why?
|
Precancerous Conditions | 1 | 2014 | 975 | 0.300 |
Why?
|
Surgical Flaps | 2 | 2018 | 1629 | 0.300 |
Why?
|
Radiographic Image Enhancement | 1 | 2011 | 885 | 0.280 |
Why?
|
Prognosis | 17 | 2021 | 29052 | 0.280 |
Why?
|
Patient Care | 1 | 2012 | 638 | 0.270 |
Why?
|
Sarcoma | 1 | 2017 | 1898 | 0.270 |
Why?
|
Survival Rate | 9 | 2020 | 12786 | 0.260 |
Why?
|
Risk Assessment | 5 | 2016 | 23327 | 0.260 |
Why?
|
Breast | 4 | 2018 | 1970 | 0.260 |
Why?
|
Extremities | 3 | 2020 | 867 | 0.250 |
Why?
|
Water | 1 | 2011 | 1394 | 0.250 |
Why?
|
Immunologic Factors | 1 | 2014 | 1580 | 0.250 |
Why?
|
Neoplasm Invasiveness | 10 | 2019 | 3617 | 0.250 |
Why?
|
Neoplastic Stem Cells | 2 | 2016 | 1376 | 0.250 |
Why?
|
Parathyroid Hormone-Related Protein | 1 | 2006 | 331 | 0.240 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.240 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2020 | 547 | 0.230 |
Why?
|
Carcinoma in Situ | 2 | 2006 | 805 | 0.230 |
Why?
|
Lower Extremity | 4 | 2020 | 1158 | 0.210 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 11524 | 0.210 |
Why?
|
Aged, 80 and over | 22 | 2020 | 57744 | 0.210 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2006 | 1100 | 0.200 |
Why?
|
Lymphedema | 2 | 2019 | 534 | 0.200 |
Why?
|
Follow-Up Studies | 13 | 2019 | 39001 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 2 | 2015 | 5532 | 0.190 |
Why?
|
Mastectomy | 2 | 2006 | 1793 | 0.190 |
Why?
|
Radiotherapy | 2 | 2020 | 1533 | 0.190 |
Why?
|
Humans | 67 | 2022 | 743811 | 0.190 |
Why?
|
Aged | 31 | 2021 | 163178 | 0.180 |
Why?
|
Middle Aged | 37 | 2021 | 213241 | 0.180 |
Why?
|
Upper Extremity | 3 | 2020 | 647 | 0.180 |
Why?
|
Subcutaneous Tissue | 1 | 2020 | 135 | 0.180 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7270 | 0.170 |
Why?
|
Female | 48 | 2021 | 380020 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2021 | 2039 | 0.160 |
Why?
|
Dactinomycin | 4 | 2020 | 318 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6539 | 0.160 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13112 | 0.160 |
Why?
|
Propranolol | 1 | 2019 | 502 | 0.160 |
Why?
|
Neoplasm Metastasis | 7 | 2020 | 4848 | 0.150 |
Why?
|
Biopsy, Fine-Needle | 2 | 2020 | 1094 | 0.150 |
Why?
|
Indoles | 2 | 2017 | 1841 | 0.150 |
Why?
|
Mammary Glands, Human | 2 | 2016 | 199 | 0.150 |
Why?
|
Phlebotomy | 1 | 2018 | 141 | 0.150 |
Why?
|
Stromal Cells | 2 | 2015 | 1356 | 0.140 |
Why?
|
Adult | 30 | 2021 | 213889 | 0.140 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2019 | 627 | 0.140 |
Why?
|
Manikins | 1 | 2018 | 238 | 0.140 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2017 | 933 | 0.140 |
Why?
|
Punctures | 1 | 2018 | 374 | 0.140 |
Why?
|
Quality Improvement | 1 | 2012 | 3750 | 0.140 |
Why?
|
Collagenases | 1 | 2016 | 228 | 0.140 |
Why?
|
Rose Bengal | 1 | 2016 | 116 | 0.130 |
Why?
|
Male | 28 | 2021 | 349776 | 0.130 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13691 | 0.130 |
Why?
|
Epithelium | 3 | 2018 | 1679 | 0.130 |
Why?
|
Scalp | 1 | 2018 | 378 | 0.130 |
Why?
|
Retrospective Studies | 14 | 2022 | 77410 | 0.130 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2016 | 200 | 0.130 |
Why?
|
Immunohistochemistry | 7 | 2021 | 11360 | 0.120 |
Why?
|
Liposarcoma | 1 | 2017 | 333 | 0.120 |
Why?
|
Disease Management | 3 | 2021 | 2459 | 0.120 |
Why?
|
Hydroxamic Acids | 1 | 2017 | 494 | 0.120 |
Why?
|
Necrosis | 1 | 2018 | 1642 | 0.120 |
Why?
|
Morbidity | 1 | 2019 | 1768 | 0.120 |
Why?
|
Neck Dissection | 1 | 2014 | 197 | 0.110 |
Why?
|
Skin Transplantation | 1 | 2018 | 1074 | 0.110 |
Why?
|
Axilla | 3 | 2010 | 597 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2016 | 2942 | 0.100 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 4749 | 0.100 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2017 | 789 | 0.100 |
Why?
|
Prospective Studies | 10 | 2019 | 53250 | 0.100 |
Why?
|
Interdisciplinary Communication | 1 | 2017 | 950 | 0.100 |
Why?
|
Survival Analysis | 6 | 2020 | 10251 | 0.100 |
Why?
|
New Zealand | 1 | 2012 | 355 | 0.100 |
Why?
|
Hospital Information Systems | 1 | 2013 | 395 | 0.100 |
Why?
|
Adsorption | 1 | 2011 | 201 | 0.100 |
Why?
|
Diagnosis, Differential | 2 | 2017 | 12954 | 0.090 |
Why?
|
Organoids | 1 | 2016 | 701 | 0.090 |
Why?
|
Immunomodulation | 1 | 2014 | 541 | 0.090 |
Why?
|
Disease-Free Survival | 3 | 2016 | 6895 | 0.090 |
Why?
|
Feasibility Studies | 2 | 2018 | 5078 | 0.090 |
Why?
|
Carcinoma, Ductal | 1 | 2010 | 101 | 0.090 |
Why?
|
Receptor, erbB-2 | 2 | 2017 | 2418 | 0.080 |
Why?
|
Biopsy | 2 | 2019 | 6750 | 0.080 |
Why?
|
Surface Properties | 1 | 2011 | 1168 | 0.080 |
Why?
|
Fluorescent Dyes | 1 | 2016 | 1903 | 0.080 |
Why?
|
Pilot Projects | 2 | 2018 | 8316 | 0.080 |
Why?
|
Immunotherapy | 2 | 2019 | 4437 | 0.080 |
Why?
|
Dermatology | 1 | 2018 | 872 | 0.080 |
Why?
|
Medical Order Entry Systems | 1 | 2013 | 545 | 0.080 |
Why?
|
Watchful Waiting | 1 | 2012 | 491 | 0.080 |
Why?
|
Caveolin 1 | 1 | 2009 | 263 | 0.070 |
Why?
|
Medication Errors | 1 | 2013 | 798 | 0.070 |
Why?
|
Cause of Death | 1 | 2018 | 3580 | 0.070 |
Why?
|
Thyroid Neoplasms | 1 | 2020 | 2282 | 0.070 |
Why?
|
Collagen | 1 | 2015 | 2681 | 0.070 |
Why?
|
Neoadjuvant Therapy | 1 | 2017 | 2727 | 0.070 |
Why?
|
Phenotype | 3 | 2019 | 16361 | 0.070 |
Why?
|
Tissue Engineering | 1 | 2016 | 1880 | 0.070 |
Why?
|
Carcinoma, Lobular | 1 | 2010 | 484 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 2291 | 0.070 |
Why?
|
Sulfonamides | 1 | 2015 | 1938 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2010 | 956 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2022 | 21733 | 0.060 |
Why?
|
Immunity, Innate | 1 | 2017 | 2961 | 0.060 |
Why?
|
Treatment Outcome | 9 | 2020 | 63042 | 0.060 |
Why?
|
Age Factors | 2 | 2020 | 18355 | 0.060 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4033 | 0.060 |
Why?
|
Microarray Analysis | 1 | 2007 | 765 | 0.060 |
Why?
|
RNA, Neoplasm | 2 | 2004 | 769 | 0.060 |
Why?
|
Recurrence | 1 | 2015 | 8337 | 0.060 |
Why?
|
Guidelines as Topic | 2 | 2021 | 1404 | 0.060 |
Why?
|
Nerve Tissue Proteins | 1 | 2016 | 4463 | 0.060 |
Why?
|
Length of Stay | 2 | 2020 | 6311 | 0.060 |
Why?
|
Young Adult | 7 | 2020 | 56392 | 0.050 |
Why?
|
Sialoglycoproteins | 1 | 2004 | 318 | 0.050 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2004 | 460 | 0.050 |
Why?
|
Risk Factors | 5 | 2019 | 72252 | 0.050 |
Why?
|
Cell Division | 2 | 2007 | 4568 | 0.050 |
Why?
|
Gene Dosage | 2 | 2004 | 1252 | 0.050 |
Why?
|
Cohort Studies | 7 | 2020 | 40545 | 0.050 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2003 | 437 | 0.050 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2003 | 440 | 0.050 |
Why?
|
Mice, SCID | 2 | 2016 | 2718 | 0.050 |
Why?
|
Interferon-alpha | 1 | 2004 | 895 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2004 | 1097 | 0.040 |
Why?
|
Chromosome Deletion | 1 | 2004 | 1396 | 0.040 |
Why?
|
Tourniquets | 1 | 2020 | 110 | 0.040 |
Why?
|
Tumor Cells, Cultured | 4 | 2016 | 6311 | 0.040 |
Why?
|
RNA, Messenger | 4 | 2016 | 13028 | 0.040 |
Why?
|
Receptors, Estrogen | 2 | 2009 | 2190 | 0.040 |
Why?
|
Inflammation | 1 | 2018 | 10629 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3547 | 0.040 |
Why?
|
Urban Population | 1 | 2006 | 2021 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
Creatine Kinase | 1 | 2020 | 694 | 0.040 |
Why?
|
National Health Programs | 1 | 2021 | 445 | 0.040 |
Why?
|
Incidence | 2 | 2014 | 20948 | 0.040 |
Why?
|
Mass Screening | 2 | 2019 | 5251 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2003 | 3917 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9272 | 0.040 |
Why?
|
Extracorporeal Circulation | 1 | 2017 | 182 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2013 | 4467 | 0.040 |
Why?
|
Comorbidity | 1 | 2011 | 10380 | 0.040 |
Why?
|
Cell Proliferation | 3 | 2017 | 10477 | 0.040 |
Why?
|
Rural Population | 1 | 2006 | 2207 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15281 | 0.030 |
Why?
|
Skin Ulcer | 1 | 2017 | 120 | 0.030 |
Why?
|
Injections, Intralesional | 1 | 2016 | 276 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 973 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2019 | 690 | 0.030 |
Why?
|
Estrogens | 1 | 2002 | 1563 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2017 | 793 | 0.030 |
Why?
|
Estradiol | 1 | 2002 | 2017 | 0.030 |
Why?
|
Tumor Burden | 1 | 2020 | 1917 | 0.030 |
Why?
|
Stem Cells | 1 | 2007 | 3566 | 0.030 |
Why?
|
Glycoproteins | 1 | 2002 | 2266 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2020 | 1275 | 0.030 |
Why?
|
Bone Neoplasms | 1 | 2006 | 2529 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2018 | 794 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2384 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2016 | 402 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4183 | 0.030 |
Why?
|
Drug Synergism | 1 | 2017 | 1794 | 0.030 |
Why?
|
Queensland | 1 | 2012 | 37 | 0.030 |
Why?
|
Lymphatic Vessels | 1 | 2017 | 353 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2018 | 1142 | 0.030 |
Why?
|
Ultrasonography, Interventional | 1 | 2020 | 1486 | 0.030 |
Why?
|
Macrophages | 2 | 2018 | 5651 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10940 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1876 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2018 | 1148 | 0.030 |
Why?
|
Mitosis | 1 | 2017 | 1207 | 0.020 |
Why?
|
Ischemia | 1 | 2020 | 1907 | 0.020 |
Why?
|
Blood Vessels | 1 | 2017 | 1124 | 0.020 |
Why?
|
United States | 4 | 2020 | 69859 | 0.020 |
Why?
|
Animals | 6 | 2017 | 168660 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1880 | 0.020 |
Why?
|
Cell Line, Tumor | 3 | 2017 | 16674 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2015 | 713 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2015 | 1340 | 0.020 |
Why?
|
Immunosorbent Techniques | 1 | 2009 | 184 | 0.020 |
Why?
|
Mice | 5 | 2017 | 81154 | 0.020 |
Why?
|
Intraoperative Period | 1 | 2010 | 520 | 0.020 |
Why?
|
Trust | 1 | 2013 | 505 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5179 | 0.020 |
Why?
|
Commerce | 1 | 2013 | 592 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2012 | 1586 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2504 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2017 | 2131 | 0.020 |
Why?
|
Child, Preschool | 2 | 2020 | 40964 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15067 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2004 | 2649 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2018 | 2720 | 0.020 |
Why?
|
Victoria | 1 | 2006 | 67 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2003 | 9440 | 0.020 |
Why?
|
Cell Survival | 1 | 2017 | 5881 | 0.020 |
Why?
|
Child | 3 | 2020 | 77637 | 0.020 |
Why?
|
Medical Informatics | 1 | 2013 | 745 | 0.020 |
Why?
|
Microspheres | 1 | 2009 | 777 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10394 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2971 | 0.020 |
Why?
|
Magnetics | 1 | 2009 | 604 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2019 | 4477 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5973 | 0.020 |
Why?
|
Receptors, Virus | 1 | 2009 | 649 | 0.020 |
Why?
|
Mutation | 2 | 2021 | 29777 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 7908 | 0.020 |
Why?
|
Adolescent | 3 | 2020 | 85729 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2018 | 4665 | 0.020 |
Why?
|
Time Factors | 2 | 2020 | 40038 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2134 | 0.020 |
Why?
|
Receptors, Progesterone | 1 | 2009 | 1098 | 0.020 |
Why?
|
Integrin-Binding Sialoprotein | 1 | 2004 | 23 | 0.020 |
Why?
|
Data Collection | 1 | 2013 | 3339 | 0.010 |
Why?
|
Cell Separation | 1 | 2009 | 1750 | 0.010 |
Why?
|
Glucose Transport Proteins, Facilitative | 1 | 2003 | 55 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2019 | 8939 | 0.010 |
Why?
|
Paraffin Embedding | 1 | 2003 | 299 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 1 | 2003 | 1374 | 0.010 |
Why?
|
Continuity of Patient Care | 1 | 2007 | 1049 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2018 | 19894 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9718 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 2004 | 2085 | 0.010 |
Why?
|
Neck | 1 | 2004 | 698 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2004 | 1639 | 0.010 |
Why?
|
Gene Amplification | 1 | 2003 | 1063 | 0.010 |
Why?
|
Infant | 1 | 2020 | 35122 | 0.010 |
Why?
|
Biological Transport | 1 | 2003 | 2119 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12243 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 25032 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2017 | 18027 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 12354 | 0.010 |
Why?
|
Mice, Nude | 1 | 2004 | 3680 | 0.010 |
Why?
|
Models, Animal | 1 | 2004 | 2172 | 0.010 |
Why?
|
Oncogenes | 1 | 2003 | 1265 | 0.010 |
Why?
|
Reference Values | 1 | 2004 | 4974 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2009 | 9731 | 0.010 |
Why?
|
Menopause | 1 | 2004 | 1626 | 0.010 |
Why?
|
Transfection | 1 | 2004 | 5892 | 0.010 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2003 | 948 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2009 | 3089 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2004 | 6380 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2002 | 1678 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2003 | 4737 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6620 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6170 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2009 | 14563 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23398 | 0.010 |
Why?
|
Registries | 1 | 2007 | 8090 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2002 | 2850 | 0.010 |
Why?
|
Glucose | 1 | 2003 | 4398 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2003 | 8430 | 0.000 |
Why?
|
Proteins | 1 | 2002 | 6098 | 0.000 |
Why?
|